Clinical Trials
12 trialsNCT04690699 2024-10-24
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Istari Oncology, Inc.
Phase 1/2 Terminated
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03498196 2020-08-24
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Baylor College of Medicine
Phase 1/2 Terminated
NCT03719300 2020-08-19
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT03167151 2020-07-31
PemBla
University of Oxford
Phase 1/2 Terminated
NCT02605863 2018-10-03
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Phase 2 Terminated
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated